1
|
Kosasih HJ, Healey G, Brennan MS, Bjelosevic S, Sadras T, Jalud FB, Ibnat T, Ng AP, Mayoh C, Mao J, Tax G, Ludlow LEA, Johnstone RW, Herold MJ, Khaw SL, de Bock CE, Ekert PG. A novel MYB::PAIP1 oncogenic fusion in pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN) is dependent on BCL2 expression and is sensitive to venetoclax. Hemasphere 2024; 8:e1. [PMID: 38435422 PMCID: PMC10878182 DOI: 10.1002/hem3.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Accepted: 12/16/2023] [Indexed: 03/05/2024] Open
Affiliation(s)
- Hansen J. Kosasih
- Murdoch Children's Research InstituteParkvilleVictoriaAustralia
- Children's Cancer Institute, Lowy Cancer Research CentreUNSW SydneyKensingtonNew South WalesAustralia
| | - Gerry Healey
- The Walter and Eliza Hall Institute of Medical ResearchParkvilleVictoriaAustralia
- Olivia Newton‐John Cancer Research InstituteHeidelbergVictoriaAustralia
| | - Margs S. Brennan
- The Walter and Eliza Hall Institute of Medical ResearchParkvilleVictoriaAustralia
- Department of Medicine Huddinge, Centre for Haematology and Regenerative MedicineKarolinska InstitutetStockholmSweden
| | - Stefan Bjelosevic
- Peter MacCallum Cancer CentreMelbourneVictoriaAustralia
- The Sir Peter MacCallum Department of OncologyUniversity of MelbourneParkvilleVictoriaAustralia
| | - Teresa Sadras
- Peter MacCallum Cancer CentreMelbourneVictoriaAustralia
- The Sir Peter MacCallum Department of OncologyUniversity of MelbourneParkvilleVictoriaAustralia
| | | | - Tasnia Ibnat
- Peter MacCallum Cancer CentreMelbourneVictoriaAustralia
| | - Ashley P. Ng
- The Walter and Eliza Hall Institute of Medical ResearchParkvilleVictoriaAustralia
- The Sir Peter MacCallum Department of OncologyUniversity of MelbourneParkvilleVictoriaAustralia
- Department of BiologyThe University of MelbourneParkvilleVictoriaAustralia
| | - Chelsea Mayoh
- Children's Cancer Institute, Lowy Cancer Research CentreUNSW SydneyKensingtonNew South WalesAustralia
| | - Jie Mao
- Children's Cancer Institute, Lowy Cancer Research CentreUNSW SydneyKensingtonNew South WalesAustralia
| | - Gabor Tax
- Children's Cancer Institute, Lowy Cancer Research CentreUNSW SydneyKensingtonNew South WalesAustralia
- School of Clinical Medicine, UNSW Medicine & HealthUNSW SydneySydneyNew South WalesAustralia
| | - Louise E. A. Ludlow
- Murdoch Children's Research InstituteParkvilleVictoriaAustralia
- Department of PaediatricsUniversity of MelbourneParkvilleVictoriaAustralia
| | - Ricky W. Johnstone
- Peter MacCallum Cancer CentreMelbourneVictoriaAustralia
- The Sir Peter MacCallum Department of OncologyUniversity of MelbourneParkvilleVictoriaAustralia
| | - Marco J. Herold
- The Walter and Eliza Hall Institute of Medical ResearchParkvilleVictoriaAustralia
- Olivia Newton‐John Cancer Research InstituteHeidelbergVictoriaAustralia
- Department of Medical BiologyUniversity of MelbourneParkvilleVictoriaAustralia
- School of Cancer MedicineLa Trobe UniversityHeidelbergVictoriaAustralia
| | - Seong L. Khaw
- Murdoch Children's Research InstituteParkvilleVictoriaAustralia
| | - Charles E. de Bock
- Children's Cancer Institute, Lowy Cancer Research CentreUNSW SydneyKensingtonNew South WalesAustralia
- School of Women's and Children's HealthUNSW SydneyKensingtonNew South WalesAustralia
| | - Paul G. Ekert
- Children's Cancer Institute, Lowy Cancer Research CentreUNSW SydneyKensingtonNew South WalesAustralia
- Peter MacCallum Cancer CentreMelbourneVictoriaAustralia
- The Sir Peter MacCallum Department of OncologyUniversity of MelbourneParkvilleVictoriaAustralia
- School of Clinical Medicine, UNSW Medicine & HealthUNSW SydneySydneyNew South WalesAustralia
| |
Collapse
|
2
|
Tsoli M, Shen H, Mayoh C, Franshaw L, Ehteda A, Upton D, Carvalho D, Vinci M, Meel MH, van Vuurden D, Plessier A, Castel D, Drissi R, Farrell M, Cryan J, Crimmins D, Caird J, Pears J, Francis S, Ludlow LEA, Carai A, Mastronuzzi A, Liu B, Hansford J, Gottardo N, Hassall T, Kirby M, Fouladi M, Hawkins C, Monje M, Grill J, Jones C, Hulleman E, Ziegler DS. International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. J Neurooncol 2019; 141:253-263. [PMID: 30446898 DOI: 10.1007/s11060-018-03038-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Accepted: 10/24/2018] [Indexed: 10/27/2022]
Abstract
PURPOSE Diffuse intrinsic pontine glioma is the most aggressive form of high grade glioma in children with no effective therapies. There have been no improvements in survival in part due poor understanding of underlying biology, and lack of representative in vitro and in vivo models. Recently, it has been found feasible to use both biopsy and autopsy tumors to generate cultures and xenograft models. METHODS To further model development, we evaluated the collective international experience from 8 collaborating centers to develop DIPG pre-clinical models from patient-derived autopsies and biopsies. Univariate and multivariate analysis was performed to determine key factors associated with the success of in vitro and in vivo PDX development. RESULTS In vitro cultures were successfully established from 57% of samples (84.2% of biopsies and 38.2% of autopsies). Samples transferred in DMEM media were more likely to establish successful culture than those transported in Hibernate A. In vitro cultures were more successful from biopsies (84.2%) compared with autopsies (38.2%) and as monolayer on laminin-coated plates than as neurospheres. Primary cultures successfully established from autopsy samples were more likely to engraft in animal models than cultures established from biopsies (86.7% vs. 47.4%). Collectively, tumor engraftment was more successful when DIPG samples were directly implanted in mice (68%), rather than after culturing (40.7%). CONCLUSION This multi-center study provides valuable information on the success rate of establishing patient-derived pre-clinical models of DIPG. The results can lead to further optimization of DIPG model development and ultimately assist in the investigation of new therapies for this aggressive pediatric brain tumor.
Collapse
Affiliation(s)
- Maria Tsoli
- Children's Cancer Institute, Randwick, NSW, 2031, Australia
| | - Han Shen
- Children's Cancer Institute, Randwick, NSW, 2031, Australia
| | - Chelsea Mayoh
- Children's Cancer Institute, Randwick, NSW, 2031, Australia
| | - Laura Franshaw
- Children's Cancer Institute, Randwick, NSW, 2031, Australia
| | - Anahid Ehteda
- Children's Cancer Institute, Randwick, NSW, 2031, Australia
| | - Danielle Upton
- Children's Cancer Institute, Randwick, NSW, 2031, Australia
| | - Diana Carvalho
- Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK
| | - Maria Vinci
- Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK
| | - Michael H Meel
- Department of Pediatric Oncology, VU University Medical Center, Amsterdam, the Netherlands
| | - Dannis van Vuurden
- Department of Pediatric Oncology, VU University Medical Center, Amsterdam, the Netherlands
| | - Alexander Plessier
- Unite Mixte de Recherche 8203 du Centre National de la Recherche Scientifique (CNRS) et Departement de Cancerologie de l'Enfant et de l'Adolescent, Gustave Roussy et Universite Paris-Saclay, Villejuif, France
| | - David Castel
- Unite Mixte de Recherche 8203 du Centre National de la Recherche Scientifique (CNRS) et Departement de Cancerologie de l'Enfant et de l'Adolescent, Gustave Roussy et Universite Paris-Saclay, Villejuif, France
| | - Rachid Drissi
- Brain Tumor Center, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, USA
| | - Michael Farrell
- Histopathology Department, Beaumont Hospital, Dublin, Ireland
| | - Jane Cryan
- Histopathology Department, Beaumont Hospital, Dublin, Ireland
| | - Darach Crimmins
- Department of Neurosurgery, Temple Street Children's University Hospital, Dublin, Ireland
| | - John Caird
- Department of Neurosurgery, Temple Street Children's University Hospital, Dublin, Ireland
| | - Jane Pears
- Our Lady's Children's Hospital, Dublin, Ireland
| | - Stephanie Francis
- Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, 2052, Australia
| | - Louise E A Ludlow
- Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, VIC, 3052, Australia
| | - Andrea Carai
- Neurosurgery Unit, Department of Neuroscience and Neurorehabilitation, Bambino Gesù Children's Hospital, Rome, Italy
| | - Angela Mastronuzzi
- Neuro-Oncology Unit, Department of Hemato-Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Rome, Italy
| | - Bing Liu
- Children's Cancer Institute, Randwick, NSW, 2031, Australia
| | - Jordan Hansford
- Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, VIC, 3052, Australia
| | - Nick Gottardo
- Department of Oncology, Princess Margaret Hospital, Perth, WA, Australia
| | - Tim Hassall
- Lady Cilento Children's Hospital, Brisbane, Australia
| | - Maria Kirby
- Department of Haematology-Oncology, Women's and Children's Hospital, Adelaide, SA, Australia
| | - Maryam Fouladi
- Brain Tumor Center, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, USA
| | - Cynthia Hawkins
- The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada
| | - Michelle Monje
- Stanford University and Lucile Packard Children's Hospital, Palo Alto, CA, USA
| | - Jacques Grill
- Unite Mixte de Recherche 8203 du Centre National de la Recherche Scientifique (CNRS) et Departement de Cancerologie de l'Enfant et de l'Adolescent, Gustave Roussy et Universite Paris-Saclay, Villejuif, France
| | - Chris Jones
- Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK
| | - Esther Hulleman
- Unite Mixte de Recherche 8203 du Centre National de la Recherche Scientifique (CNRS) et Departement de Cancerologie de l'Enfant et de l'Adolescent, Gustave Roussy et Universite Paris-Saclay, Villejuif, France
| | - David S Ziegler
- Children's Cancer Institute, Randwick, NSW, 2031, Australia.
- Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, 2052, Australia.
| |
Collapse
|
3
|
Ludlow LEA, Johnstone RW, Clarke CJP. The HIN-200 family: More than interferon-inducible genes? Exp Cell Res 2005; 308:1-17. [PMID: 15896773 DOI: 10.1016/j.yexcr.2005.03.032] [Citation(s) in RCA: 138] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2004] [Revised: 03/04/2005] [Accepted: 03/14/2005] [Indexed: 10/25/2022]
Abstract
The HIN-200 family was initially grouped together based on their hemopoietic expression, interferon-inducibility, nuclear localization, and characteristic 200 amino-acid domains. In this review, we performed a comprehensive search of genome databases and determined the location of previously characterized and predicted genes within the human, mouse, and rat HIN-200 loci. Several novel proteins were predicted in the mouse and rat. We also discuss recent advances in our understanding of this family of proteins and highlight the most important findings. In addition to a role in interferon biology, there is now good evidence supporting a role for these proteins as regulators of cell proliferation and differentiation. The activity of HIN-200 proteins is not restricted to the hemopoietic system as they are expressed and can function in a variety of other cells and tissues. The importance of HIN-200 proteins in disease now is beginning to be understood as they appear to be involved in autoimmunity and may act as tumor suppressor proteins.
Collapse
Affiliation(s)
- Louise E A Ludlow
- Cancer Immunology Division, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, 8006, Victoria, Australia
| | | | | |
Collapse
|